Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed locally advanced or metastatic urothelial carcinoma~* Expression of LHRH receptors confirmed by immunohistochemistry on archival cancer tissue~* Measurable disease on radiological studies~* Patients with Locally advanced unresectable or metastatic urothelial carcinoma~* Documented progression on at least one prior chemotherapy regimen which must have incorporated platinum based therapy~* Left ventricular ejection fraction (EF) \> 50%~* Eastern cooperative oncology group (ECOG) status of 0, 1 or 2~* Adequate bone marrow, renal and hepatic function~Exclusion Criteria:~* Prior treatment with or allergy to any components of AEZS-108~* Active second malignancies other than non-melanoma skin cancers~* Ongoing use of an LHRH agonist (or antagonist)~* Presence of an active infection or fever \> 38.5 C, parenchymal brain metastases or uncontrolled intercurrent illness~* Prior exposure to anthracyclines or anthracenediones including doxorubicin, daunorubicin, and mitoxantrone~* Patients who received radiotherapy within 4 weeks of entry~* Major surgery within the last 4 weeks and minor surgery in last 7 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1 - Cohort 1 (Type: EXPERIMENTAL): Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).~Patients will be enrolled in cohorts of 3 at a specified AEZS-108 dose beginning with 160mg/m\^2. Enrollment will be suspended until all members of a cohort have been observed for dose limiting toxicities (DLT) for a period of 3 weeks (1 cycle of AEZS-108) from initial treatment with AEZS-108. Dose escalation will proceed within each cohort according to a specific scheme where DLT is defined.
- Phase 1 - Cohort 2 (Type: EXPERIMENTAL): Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
- Phase 1 - Cohort 3 (Type: EXPERIMENTAL): Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
- Phase 1 - Cohort 4 (Type: EXPERIMENTAL): Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
- Phase 2 (Type: EXPERIMENTAL): AEZS-108 at MTD to determine efficacy in up to 40 patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).